Business Context and Reporting Period
This Form 8-K was filed by Aligos Therapeutics, Inc. on September 7, 2023, reporting an event that occurred on September 5, 2023. The Company is a Delaware corporation with its principal executive offices in South San Francisco, CA, and its common stock trades on the Nasdaq Global Select Market under the symbol "ALGS".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory compliance issue regarding the Company's stock price.
Material Changes
The material event reported is the receipt of a written notice from the Nasdaq Listing Qualifications Department. The notice states that the Company's common stock failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days between July 21, 2023, and September 1, 2023, violating Nasdaq Listing Rule 5450(a)(1).
Guidance, Outlook, and Risks
- Compliance Period: The Company has been granted an initial 180-calendar-day compliance period, ending on March 4, 2024, to regain compliance.
- Requirements to Cure: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to the compliance date.
- Secondary Compliance Option: If the Company fails to meet the initial requirement, it may be eligible for an additional 180-day period. This would require transferring its listing to the Nasdaq Capital Market and meeting all applicable initial listing standards for that market, except the minimum bid price requirement.
- Potential Actions: The Company may consider a reverse stock split or other options to cure the deficiency, though there is no assurance of success.
- Delisting Risk: If the Company cannot cure the deficiency or meet other listing standards, Nasdaq may issue a delisting notice. The Company retains the right to appeal such a determination to a Nasdaq Hearing Panel, with no assurance of a successful appeal.
Investor Verification Checklist
- Verify the current closing bid price of ALGS stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if the initial cure condition is met.
- Review future filings for announcements regarding a potential reverse stock split or transfer to the Nasdaq Capital Market.
- Check for any subsequent notices from Nasdaq regarding the Company's ability to cure the deficiency or potential delisting determinations.